Publications

Featured Publication

Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia

N Engl J Med 2021; 384:717-726

Brannan, S.K., Sawchak, S., et al.

View

The Potential Role of the M1/M4 Muscarinic Receptor Agonist KarXT in the Treatment of Cognitive Impairment in Patients With Schizophrenia

36th European College of Neuropsychopharmacology (ECNP) Congress; 2023 October 7-10.

Horan W., Harvey, D., et al.

View

Evidence of trospium’s ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results

Psychopharmacology (2023)

Breier, A., Brannan, SK., et al.

View

Structural Basis of Efficacy-Driven Ligand Selectivity at GPCRs

Nature Chem Biol 2023

Powers, A. S., Pham, V., et al.

View

The Clinical Candidate Xanomeline Displays a Binate Orthosteric and Allosteric Binding and Pharmacological Profile at the M4 mACHR

American College of Psychopharmacology (ACNP) Annual Meeting; 2022 December 4-7.

Burger, W., Vuckovic, Z., et al.

View

Safety and Tolerability of KarXT (Xanomeline-Trospium) in a Phase 2, Randomized, Double-blind, Placebo-controlled Study in Patients with Schizophrenia

Schizophr 2022; 8:109

Correll, C., Angelov, A., et al.

View

Safety and Efficacy of KarXT (Xanomeline-Trospium) in Patients With Schizophrenia: Results From a Phase 3, Randomized, Double-blind, Placebo-controlled Trial (EMERGENT-2)

American College of Psychopharmacology (ACNP) Annual Meeting; 2022 December 4-7.

Paul, S., Correll, C., et al.

View

Effectiveness of KarXT (Xanomeline-Trospium) for Cognitive Impairment in Schizophrenia: Post Hoc Analyses from a Randomised, Double-blind, Placebo-controlled Phase 2 Study

Transl Psychiatry 12, 491 (2022).

Sauder, C., Allen L. A., et al.

View

1 2 3 4 5